- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01419990
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy Subjects
Double-blind Placebo Controlled Dose-ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Dosing of GLPG0634 in Healthy Subjects
The purpose of the study is to evaluate the safety and tolerability of multiple ascending oral doses of GLPG0634 given to healthy subjects for 10 days compared to placebo.
During the course of the study, the amount of GLPG0634 present in the blood (pharmacokinetics) as well as the effects of GLPG0634 on mechanism of action-related parameters in the blood (pharmacodynamics) will be characterized.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Antwerp, Belgium, 2060
- SGS Stuivenberg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male, age 40-60 years
- BMI between 18-30 kg/m2
Exclusion Criteria:
- Any condition that might interfere with the procedures or tests in this study
- Drug or alcohol abuse
- Smoking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo capsules
|
Placebo oral capsules, qd, 10 days
|
Experimental: GLPG0634 capsules
|
GLPG0634 300 mg oral capsules, qd, 10 days
GLPG0634 450 mg oral capsules, qd, 10 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability
Time Frame: From screening up to 10 days after the last dose
|
To evaluate the safety and tolerability of GLPG0634 in comparison with placebo after multiple oral doses in healthy subjects in terms of adverse events, physical examinations, vital signs, ECG and lab assessments
|
From screening up to 10 days after the last dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK) and pharmacodynamics (PD)
Time Frame: From first dose up to 10 days after the last dose
|
To determine the plasma levels of GLPG0634 as a measure of PK and the levels of immune- and inflammation-related parameters as a measure of PD
|
From first dose up to 10 days after the last dose
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- GLPG0634-CL-102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on GLPG0634
-
Galapagos NVCompletedRenal ImpairmentGermany
-
Galapagos NVCompletedHealthyUnited Kingdom
-
Galapagos NVCompletedCrohn's DiseaseUnited Kingdom, Belgium, France, Hungary, Russian Federation, Czech Republic, Germany, Poland, Romania
-
Gilead SciencesGalapagos NVCompletedRheumatoid ArthritisUnited States, Germany, New Zealand
-
Galapagos NVRecruitingJuvenile Idiopathic ArthritisSpain, Germany, United Kingdom, France, Poland
-
Galapagos NVTerminatedUlcerative ColitisUnited States, Germany, Korea, Republic of, Spain, France, Hungary, United Kingdom, Poland, Belgium, Czechia, Italy, South Africa, Taiwan
-
Galapagos NVGilead SciencesActive, not recruitingUlcerative ColitisUnited States, Netherlands, Israel, Spain, Taiwan, Australia, Italy, Hong Kong, Singapore, Korea, Republic of, Canada, Germany, United Kingdom, New Zealand, Ireland, Poland, Romania, Croatia, Belgium, Japan, India, Malaysia, Sweden, F... and more
-
Galapagos NVRecruitingAxial SpondyloarthritisBelgium, Korea, Republic of, Germany, Netherlands, France, Taiwan, Greece, United Kingdom, Italy, Bulgaria, South Africa, Estonia, Spain, Hungary, Czechia, Lithuania, Philippines, Poland, Romania, Croatia
-
Galapagos NVGilead SciencesCompletedCrohn's DiseaseHong Kong, United States, Netherlands, Belgium, France, Israel, Spain, Korea, Republic of, Taiwan, Germany, Australia, United Kingdom, Italy, India, Singapore, Portugal, Malaysia, New Zealand, Serbia, Ireland, Poland, Romania, Japan, ... and more